Diligence memo · auto-generated · as of July 3, 2026
Gilgamesh Pharmaceuticals, Inc.
Gilgamesh Pharmaceuticals, Inc. looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Gilgamesh Pharmaceuticals, Inc. operates in Pharmaceuticals, based in New York, NY, USA; Remote. Gilgamesh Pharmaceuticals, a Clinical stage biotechnology company…
Sub-sector tags: biotech.
Capital & rounds (filed)filed
Gilgamesh Pharmaceuticals, Inc. has raised $52M in disclosed capital across 5 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $35M on 2021-04-26.
Most recent recorded round closed around 2022-05-16.
Valuation (modeled)modeled
Provath models Gilgamesh Pharmaceuticals, Inc. at approximately $223M (range $29M–$601M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 1.72× the median modeled value of Series B Pharmaceuticals companies in 2022–2024 (51 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 5 months.
Last raise 4.1 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round was 2.5× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 82% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 70% of those peers.
Closest niche peers: MedAvail Holdings, Inc., Revalesio Corp, Kinaset Therapeutics, Inc., Venatorx Pharmaceuticals, Inc., Cxl Ophthalmics, Inc..
Peoplefiled
14 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.